<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A combination chemotherapy program using <z:chebi fb="0" ids="44185">methotrexate</z:chebi>, <z:chebi fb="0" ids="3139">bleomycin</z:chebi>, <z:chebi fb="0" ids="28748">doxorubicin</z:chebi>, <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="28445">vincristine</z:chebi>, and <z:chebi fb="0" ids="41879">dexamethasone</z:chebi> (M-BACOD), which resulted in a high complete response rate and prolonged disease-free survival in <z:hpo ids='HP_0002665'>lymphomas</z:hpo> of the unfavorable diffuse histiocytic and diffuse undifferentiated histopathologic subgroups, was administered to 44 patients with advanced favorable and intermediate-prognosis non-Hodgkin's <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, including nodular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> of the poorly differentiated lymphocytic, mixed, and histiocytic subtypes, and diffuse <z:hpo ids='HP_0002665'>lymphoma</z:hpo> of the poorly differentiated lymphocytic or mixed histologic subtypes </plain></SENT>
<SENT sid="1" pm="."><plain>High-dose <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (3 g/m2) was given on Day 14 between cycles of <z:chebi fb="0" ids="3139">bleomycin</z:chebi>, <z:chebi fb="0" ids="28748">doxorubicin</z:chebi>, <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="28445">vincristine</z:chebi>, and <z:chebi fb="0" ids="41879">dexamethasone</z:chebi>, administered every 3 weeks for ten cycles </plain></SENT>
<SENT sid="2" pm="."><plain>Leucovorin factor (10 mg/m2) was given iv 24 hours after the <z:chebi fb="0" ids="44185">methotrexate</z:chebi> infusion was completed, and was continued at 10 mg/m2 by mouth every 6 hours for 72 hours </plain></SENT>
<SENT sid="3" pm="."><plain>Therapy was well-tolerated, with predictable <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e> in the majority of patients </plain></SENT>
<SENT sid="4" pm="."><plain>The complete response rate was 57% (25 of 44 patients), including ten of 18 (56%) patients with nodular and 15 of 26 (58%) patients with diffuse <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Median overall follow-up among living patients is 65 months, 58 months for patients with nodular and 69 months for patients with diffuse histologic subgroups </plain></SENT>
<SENT sid="6" pm="."><plain>Overall survival at 5 years was 64% for patients who achieved complete response, 32% for partial responders, and 0% for those patients who did not respond </plain></SENT>
<SENT sid="7" pm="."><plain>Disease-free survival of complete responders was 43% at 5 years, with only one disease-related <z:hpo ids='HP_0011420'>death</z:hpo> noted after 36 months </plain></SENT>
<SENT sid="8" pm="."><plain>The nodular and diffuse patient subgroups had similar overall and disease-free survivals </plain></SENT>
<SENT sid="9" pm="."><plain>Although initial bone marrow involvement was documented in nine of 18 (50%) nodular patients and in 13 of 26 (50%) diffuse patients, <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> relapse occurred in only one complete and two partial responders </plain></SENT>
<SENT sid="10" pm="."><plain>The prolonged disease-free survival observed after M-BACOD therapy demonstrates that durable responses can be achieved with intensive chemotherapy </plain></SENT>
</text></document>